Abstract

The Ly49E NK receptor is a unique inhibitory receptor, presenting with a high degree of conservation among mouse strains and expression on both NK cells and intraepithelial-localised T cells. Amongst intraepithelial-localised T cells, the Ly49E receptor is abundantly expressed on CD8αα-expressing innate-like intestinal intraepithelial lymphocytes (iIELs), which contribute to front-line defense at the mucosal barrier. Inflammatory bowel diseases (IBDs), encompassing Crohn's disease and ulcerative colitis, have previously been suggested to have an autoreactive origin and to evolve from a dysbalance between regulatory and effector functions in the intestinal immune system. Here, we made use of Ly49E-deficient mice to characterize the role of Ly49E receptor expression on CD8αα-expressing iIELs in the development and progression of IBD. For this purpose we used the dextran sodium sulphate (DSS)- and trinitrobenzenesulfonic-acid (TNBS)-induced colitis models, and the TNFΔARE ileitis model. We show that Ly49E is expressed on a high proportion of CD8αα-positive iIELs, with higher expression in the colon as compared to the small intestine. However, Ly49E expression on small intestinal and colonic iIELs does not influence the development or progression of inflammatory bowel diseases.

Highlights

  • Inflammatory bowel diseases (IBDs), encompassing Crohn’s disease and ulcerative colitis, are chronic and relapsing disorders of the gastrointestinal tract [1]

  • The frequency of Ly49E-expressing colonic TCRcd CD8aa-positive intraepithelial lymphocytes (iIELs) exceeds the frequency of Ly49E-expressing TCRcd CD8aa-positive iIELs in the small intestine, whereas we found the proportion of Ly49E-expressing TCRab CD8aapositive iIELs in the small intestine and colon to be comparable

  • In this paper we show that the Ly49E NK receptor is abundantly expressed on CD8aa-expressing iIELs of the small intestine as well as the colon

Read more

Summary

Introduction

Inflammatory bowel diseases (IBDs), encompassing Crohn’s disease and ulcerative colitis, are chronic and relapsing disorders of the gastrointestinal tract [1]. The etiology of IBD is incompletely understood, inflammatory bowel disorders are believed to present in genetically predisposed individuals exposed to undefined microbial and environmental triggers. With the highest worldwide prevalence, European figures show an estimated 1 in 200 people affected by ulcerative colitis, and 1 in 300 affected by Crohn’s disease [6,7]. Current IBD treatment options include the administration of anti-inflammatory drugs, immunosuppressives and immunobiological agents [8,9]. Additional research is required to further elucidate IBD mechanisms and facilitate the development of specific and effective new therapies

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call